Despite a surge in medical marijuana sales, Canopy Growth Corp's stock is struggling to maintain momentum.
Canopy Growth Corp (WEED.TO) saw a decline of 2.82% in the last trading session, closing at CA$1.38. This drop is surprising given the positive news about its medical marijuana segment, which has shown significant growth.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Canopy Growth Corp
WEED.TO
WEED.TO
Canopy Growth Corp
WealthAwesomeMarket cap
$614.33M
52W high
$3.28
52W low
$1.18
1W change
-1.47%
Beta
2.42
Analyst Price Targets
Based on analyst covering WEED
Wall Street analysts forecast WEED stock price to rise 50.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.02
+50.7% Upside
Current Price
C$1.34
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on WEED's historical volatility
30-Day Vol
38.4%
Annualized
90-Day Vol
64.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.12
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.26 | C$1.11 โ C$1.44 |
| 60 trading days | C$1.19 | C$0.99 โ C$1.43 |
| 90 trading days | C$1.12 | C$0.89 โ C$1.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should weigh the mixed performance across Canopy Growth's business segments and consider its recent financial challenges before making any investment decisions.
Canopy Growth Corp's stock drops 2.82% in one day.
Even with a 68% rise in international cannabis sales, overall revenue growth is being held back by supply chain issues and declining performance in key areas.
Bull case
The 27% increase in medical marijuana sales shows strong demand in the medical sector, which could lay the groundwork for future growth.
Bear case
However, the mixed results, especially in the recreational segment and declining gross margins, suggest that Canopy Growth's recovery might be tougher than expected.
Mixed Signals from Canopy Growth
Canopy Growth's recent performance highlights a stark contrast between its medical and recreational marijuana segments. While medical sales surged by 27% in the last fiscal year, the recreational segment's growth has stagnated, with only a 1% increase in the fourth quarter. This inconsistency raises questions about the company's ability to sustain momentum across its diverse business lines.
Financial Struggles Persist
Despite some positive signs, Canopy Growth continues to face significant financial challenges. The company's gross margin has declined, and it has reported negative earnings for over a decade. Investors should be cautious, as the recent recapitalization efforts indicate that the company is still struggling with its financial health. The overall outlook remains uncertain, making it a risky bet for potential investors.
Advertisement
